CD8A and leukemia: To determine whether the superior leukemia control in PBMC + DNT group is due to an additive effect of the endogenous anti-leukemic activities of CD8+ Tconv cells, the major anti-leukemia effector cells in PBMC, and DNTs or a synergy between these two cell types, CD8+ T cells were isolated from PBMC + PBS and PBMC + DNT treated mice and used as effector cells against the same leukemic cell line (MV4-11) for the AML-xenograft model.